#1 Clinical Trials Search in Europe

Bi 3720931

This article explores the clinical trials of BI 3720931, an innovative inhaled lentiviral vector gene therapy for cystic fibrosis (CF) patients who are ineligible for CFTR modulators. The trials aim to assess the safety, tolerability, and efficacy of this new treatment, offering hope for improved lung function and quality of life for individuals with CF. We’ll delve into the key aspects of these trials, including their objectives, eligibility criteria, and potential outcomes.

Table of Contents

What is BI 3720931?

BI 3720931 is a new and promising gene therapy being developed for the treatment of cystic fibrosis (CF). It is classified as an inhaled lentiviral vector gene therapy, which means it uses a modified virus to deliver genetic material to cells in the lungs.[1] This therapy aims to address the underlying genetic cause of cystic fibrosis, potentially offering a new treatment option for patients who cannot use or benefit from existing CF treatments.

How is BI 3720931 administered?

BI 3720931 is administered as a nebuliser solution, which means it is inhaled as a mist directly into the lungs. The medication is delivered using a special device called a nebulizer.[1] This method of administration allows the therapy to reach the affected lung cells directly, potentially increasing its effectiveness.

Who can benefit from BI 3720931?

This therapy is being developed for adults with cystic fibrosis who are not eligible for or cannot use CFTR modulators (another type of CF treatment). Specifically, it may benefit patients who:[1]

  • Have a confirmed diagnosis of CF with a positive sweat chloride test or specific genetic mutations
  • Are not eligible for CFTR modulator treatment due to their specific genetic mutations
  • Have moderate to severe lung function impairment (FEV1 between 50% and 100% of predicted normal)
  • Have stable CF disease without recent pulmonary exacerbations

Clinical Trials and Research

BI 3720931 is currently being studied in clinical trials to evaluate its safety, tolerability, and effectiveness. The research is being conducted in two main phases:[1]

  1. Phase I/II trial (LenticlairTM 1): This initial study aims to assess the safety and potential benefits of a single dose of BI 3720931. It includes both an open-label dose escalation part and a randomized, placebo-controlled expansion part.
  2. Long-term follow-up study (LenticlairTM-ON): This study will monitor patients who received BI 3720931 in the initial trial for up to 15 years to evaluate long-term safety and durability of the treatment’s effects.[2]

Safety and Side Effects

As with any new treatment, safety is a primary concern. The clinical trials are closely monitoring for any side effects or adverse events. Some key safety considerations include:[1][2]

  • Occurrence of drug-related adverse events
  • Potential dose-limiting toxicities
  • Long-term effects, including the possibility of new malignancies, serious neurologic disorders, autoimmune disorders, hematologic disorders, or infections
  • The presence of replication-competent lentivirus (a safety concern specific to this type of gene therapy)

It’s important to note that the full safety profile of BI 3720931 is still being established through ongoing research.

Potential Benefits

While the effectiveness of BI 3720931 is still being evaluated, the clinical trials are looking at several potential benefits, including:[1]

  • Improvement in lung function, measured by changes in FEV1 (forced expiratory volume in 1 second)
  • Reduction in pulmonary exacerbations (sudden worsening of CF symptoms)
  • Long-lasting effects from a single dose of treatment

Long-term Follow-up

One of the unique aspects of the BI 3720931 research program is the emphasis on long-term follow-up. Patients who receive the treatment will be monitored for up to 15 years to assess:[2]

  • Duration of the treatment’s effectiveness
  • Long-term safety profile
  • Any delayed effects or complications

This extended monitoring period will provide valuable information about the long-term benefits and risks of this new gene therapy approach for cystic fibrosis.

Aspect Details
Drug Name BI 3720931
Type of Therapy Inhaled lentiviral vector gene therapy
Target Condition Cystic Fibrosis (CF)
Patient Population Adults with CF ineligible for CFTR modulators
Administration Method Nebulizer solution (inhaled)
Primary Objectives Evaluate safety, tolerability, and efficacy (lung function improvement)
Key Efficacy Measure Change in FEV1pp (lung function)
Trial Duration Initial trial up to 24 weeks, long-term follow-up up to 15 years
Safety Monitoring Adverse events, serious adverse events, delayed adverse events

FAQ

  • What is BI 3720931 and how is it administered? BI 3720931 is an inhaled lentiviral vector gene therapy for cystic fibrosis. It is administered as a nebulizer solution, which means patients inhale the medication using a special device called a nebulizer.
  • Who is eligible for the BI 3720931 clinical trials? The trials are primarily for adult cystic fibrosis patients who are not eligible for CFTR modulator treatments due to their genetic profile. Participants must have a confirmed CF diagnosis, stable disease, and meet specific lung function criteria.
  • What are the main objectives of the BI 3720931 clinical trials? The main objectives are to evaluate the safety and tolerability of BI 3720931, as well as its efficacy in improving lung function. The trials also aim to assess long-term safety and the duration of clinical benefits over at least two years.
  • How long do the clinical trials for BI 3720931 last? The initial trial lasts up to 24 weeks, with a follow-up study that monitors participants for up to 15 years to assess long-term safety and efficacy.
  • What are the potential benefits and risks of participating in these trials? Potential benefits include improved lung function and overall health for CF patients. Risks may include treatment-related side effects, which are closely monitored throughout the trials. The long-term follow-up study aims to identify any delayed adverse events that may occur.

Ongoing Clinical Trials on Bi 3720931

  • Study on the Safety and Effectiveness of BI 3720931 for Adults with Cystic Fibrosis Who Cannot Use CFTR Modulators

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Italy The Netherlands Spain

  • Long-Term Safety Study of BI 3720931 for Patients with Cystic Fibrosis from a Previous Trial

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Italy The Netherlands Spain

Glossary

  • Cystic Fibrosis (CF): A genetic disorder that affects the lungs, pancreas, and other organs, causing thick, sticky mucus to build up and leading to various health problems.
  • CFTR modulators: Medications that target the underlying cause of cystic fibrosis by improving the function of the defective CFTR protein.
  • Lentiviral vector: A type of virus-based tool used in gene therapy to deliver genetic material into cells.
  • FEV1pp: Forced Expiratory Volume in 1 second, percent predicted. A measure of lung function used to assess the severity of lung diseases like cystic fibrosis.
  • Nebulizer: A medical device that turns liquid medication into a fine mist, allowing it to be inhaled directly into the lungs.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Pulmonary exacerbation (PEX): A worsening of respiratory symptoms in cystic fibrosis patients, often requiring additional treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-bi-3720931-for-adults-with-cystic-fibrosis-who-cannot-use-cftr-modulators/
  2. http://clinicaltrials.eu/trial/long-term-safety-study-of-bi-3720931-for-patients-with-cystic-fibrosis-from-a-previous-trial/